```
=> b reg;d que sta l7
FILE 'REGISTRY' ENTERED AT 13:20:42 ON 02 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 MAY 2008  HIGHEST RN 1018897-91-0
DICTIONARY FILE UPDATES:   1 MAY 2008  HIGHEST RN 1018897-91-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html


L5              STR
```




```
VAR G1=AK/ID
VAR G2=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E2 N  AT   6

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

STEREO ATTRIBUTES: NONE
L7           73 SEA FILE=REGISTRY SSS FUL L5

100.0% PROCESSED    2115 ITERATIONS                          73 ANSWERS
SEARCH TIME: 00.00.01



=> b hcap
FILE 'HCAPLUS' ENTERED AT 13:20:45 ON 02 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
```

FILE COVERS 1907 - 2 May 2008 VOL 148 ISS 19
FILE LAST UPDATED: 1 May 2008 (20080501/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs hitrn fhitstr l10 tot

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:182646 HCAPLUS
DN 142:280227
TI Preparation of hydroxamates as matrix metalloproteinase inhibitors
IN Pain, Gilles; Davies, Stephen John; Bombrun, Agnes
PA Vernalis Oxford Limited, UK; Laboratoires Serono S.A.
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005019194	A1	20050303	2004WO-GB003558	20040818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2004266896	A1	20050303	2004AU-000266896	20040818
CA-----2536576	A1	20050303	2004CA-002536576	20040818
EP-----1660471	A1	20060531	2004EP-000768117	20040818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP--2007503422	T	20070222	2006JP-000524410	20040818
CN-----1930139	A	20070314	2004CN-080023748	20040818
MX--2006PA01865	A	20060920	2006MX-PA001865	20060216
NO---2006001302	A	20060519	2006NO-000001302	20060322
IN--2006CN00997	A	20070615	2006IN-CN000997	20060323
US--20060281920	A1	20061214	2006US-000568433	20060808
PRAI 2003GB-000019917	A	20030823		
2003GB-000028632	A	20031210		
2004WO-GB003558	W	20040818		

OS CASREACT 142:280227; MARPAT 142:280227
GI



AB Title compds. I [wherein Ar = (un)substituted (hetero)aryl or (hetero)cycloalkyl; R = H or (cyclo)alkyl; Alk = alkylene or alkenylene; R1 and R2 link together to form (un)substituted heterocycloalkyl rings which is optionally fused to (un)substituted (hetero)cycloalkyl rings; and enantiomers, diastereoisomers, salts, hydrates or solvates thereof] were prepared as inhibitors of matrix metalloproteinases. For example, II was synthesized starting from (2S)-Hydroxysuccinic acid diisopropyl ester in several steps, which showed inhibitory activity against MMP-9, MMP-2, MMP-1 and MMP-12 with IC50 values of <100 nM, <100 nM, >10000 nM, <100 nM,

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(2S)-hydroxyhexanoic acid hydroxyamide 847038-76-0P, (3R)-[[4-Benzyl-(2S)-methylpiperazin-1-yl)carbonyl]-6-(4-fluorophenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-78-2P, (3R)-[(4-Benzyl-(2S)-isobutylpiperazin-1-yl)carbonyl]-6-(4-fluorophenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-80-6P, 4-[5-(4-Ethoxyphenyl]-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-methylpiperazine-1-carboxylic acid tert-butyl ester 847038-82-8P, 4-[5-(4-Ethoxyphenyl)-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-isobutylpiperazine-1-carboxylic acid tert-butyl ester 847038-84-0P, 4-[5-(4-Methoxyphenyl)-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-methylpiperazine-1-carboxylic acid tert-butyl ester 847038-86-2P, 4-[5-(4-Methoxyphenyl)-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-isobutylpiperazine-1-carboxylic acid tert-butyl ester 847038-88-4P, 4-[5-(4-Fluorophenyl)-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-methylpiperazine-1-carboxylic acid tert-butyl ester 847038-90-8P, 4-[5-(4-Fluorophenyl]-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-isobutylpiperazine-1-carboxylic acid tert-butyl ester 847038-92-0P, 6-(4-Ethoxyphenyl)-(2S)-methoxy-(3R)-[[4-(2-fluorophenyl]piperazin-1-yl|carbonyl]hexanoic acid hydroxyamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; prepn. of hydroxamates as MMP inhibitors)
IT 847039-40-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxamates as MMP inhibitors)
IT 847037-74-5P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(3-methoxyphenyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of hydroxamates as MMP inhibitors)
RN 847037-74-5 HCAPLUS
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-4-(3-methoxyphenyl)-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
resp. II also showed 57% inhibition of IL2-induced peritoneal recruitment of lymphocytes at the dose of 3 mg/kg (vs. 76% inhibition by dexamethasone at the dose of 1 mg/kg). In general, I are selective inhibitors of MMP-12 and MMP-9 relative to the collagenases and stromelysins. Therefore, I and pharmaceutical compns. thereof are useful in the treatment or prophylaxis of diseases or conditions primarily mediated by MMP-12 and/or MMP-9, esp. inflammatory conditions, such as multiple sclerosis and fibrosis.
IT 847037-74-5P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(3-methoxyphenyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847037-76-7P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847037-78-9P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(pyridin-2-yl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847037-80-3P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(pyridin-4-yl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847037-92-7P, (3R)-[[4-[(Benzodioxol-5-yl)methyl]piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847037-94-9P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-[(pyridin-4-yl)methyl]piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847037-96-1P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[(4-benzylpiperazin-1-yl)carbonyl]hexanoic acid hydroxyamide 847037-98-3P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(pyrimidin-2-yl)piperazin-1-yl|carbonyl]hexanoic acid hydroxyamide 847038-00-0P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(4-trifluoromethylpyrimidin-2-yl)piperazin-1-yl|carbonyl]hexanoic acid hydroxyamide 847038-02-2P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(4-chloropyrimidin-2-yl)piperazin-1-yl|carbonyl]hexanoic acid hydroxyamide 847038-04-4P, (3R)-[[4-(4,6-Dimethoxy-[1,3,5]triazin-2-yl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-06-6P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(3-trifluoromethylphenyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-08-8P 847038-19-1P 847038-21-5P, (3R)-[((3S)-Benzyl-4-benzylpiperazin-1-yl)carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-23-7P 847038-26-0P, 4-[4-[(Benzodioxol-5-yl)methyl]piperazin-1-yl]-(2S)-hydroxy-N-hydroxy-4-oxo-(3R)-(4-trifluoromethoxybenzyl)butyramide 847038-34-0P, 4-[4-[(Benzodioxol-5-yl)methyl]piperazin-1-yl]-(3R)-(4-benzyloxybenzyl)-(2S)-hydroxy-N-hydroxy-4-oxobutyramide 847038-40-8P, 6-[3,5-Bis(trifluoromethyl)phenyl]-(2S)-hydroxy-(3R)-[[4-(pyridin-2-yl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-46-4P, (3R)-[((2S)-Benzyl-4-methylpiperazin-1-yl)carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-48-6P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-[(4-trifluoromethoxyphenyl)sulfonyl]piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-50-0P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(4-tolylsulfonyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-52-2P, (3R)-[[4-[(5-Bromothien-2-yl)sulfonyl]piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-54-4P, (3R)-[[4-[(5-Phenylsulfonylthien-2-yl)sulfonyl]piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-56-6P, (3R)-[[4-(4-Butoxyphenylsulfonyl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-58-8P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(4-methoxy-2,3,6-trimethylphenylsulfonyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-60-2P, (3R)-[[4-[(3,4-Dimethoxyphenyl)sulfonyl]piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-62-4P, 6-(4-Methoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(2-fluorophenyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-64-6P, 6-(4-Methoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(pyridin-2-yl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-66-8P, 6-(4-Fluorophenyl)-(3R)-[[4-(2-fluorophenyl)piperazin-1-yl]carbonyl]-(2S)-hydroxyhexanoic acid hydroxyamide 847038-68-0P, 6-(4-Fluorophenyl)-(2S)-hydroxy-(3R)-[[4-(pyridin-2-yl)piperazin-1-yl|carbonyl]hexanoic acid hydroxyamide 847038-70-4P, (3R)-[(4-Benzyl-(2S)-methylpiperazin-1-yl)carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-72-6P, (3R)-[(4-Benzyl-(2S)-methylpiperazin-1-yl)carbonyl]-6-(4-methoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-74-8P, (3R)-[(4-Benzyl-(2S)-isobutylpiperazin-1-yl)carbonyl]-6-(4-methoxyphenyl)-

=> d bib abs hitstr l11 tot

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:101557 HCAPLUS

DN 144:171021

TI Preparation of piperazine and related N-hydroxy succinic acid diamide derivatives as metalloproteinase inhibitors with therapeutic uses

IN Swinnen, Dominique; Bombrun, Agnes; Gonzalez, Jerome; Crosignani, Stefano; Gerber, Patrick; Jorand-Lebrun, Catherine

PA Applied Research Systems Ars Holding N.V., Neth. Antilles

SO PCT Int. Appl., 203 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO-2006010751	A1	20060202	2005WO-EP053616	20050725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU-2005266313	A1	20060202	2005AU-000266313	20050725
CA-2570903	A1	20060202	2005CA-002570903	20050725
EP-1771421	A1	20070411	2005EP-000772035	20050725
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN-----1989106	A	20070627	2005CN-080025086	20050725
JP-2008507575	T	20080313	2007JP-000523074	20050725
IN-2006DN07460	A	20070622	2006IN-DN0007460	20061211
MX-----2007001022	A	20070412	2007MX-000001022	20070125
US-20080021028	A1	20080124	2007US-000572761	20070126
KR-----2007046873	A	20070503	2007KR-000704004	20070220
NO-----2007000994	A	20070426	2007NO-000000994	20070221
PRAI 2004EP-000103574	A	20040726		
2004US-005911111P	P	20040726		
2005EP-000100641	A	20050131		
2005US-00648924P	P	20050201		
2005WO-EP053616	W	20050725		

OS MARPAT 144:171021

GI



I



II

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The present invention is related to piperazine and related N-hydroxy succinic acid diamide derivs. (shown as I; variables defined below; e.g. (2S,3S)-N-hydroxy-2-hydroxy-5-methyl-3-[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]hexanamide (shown as II)) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis. A = -C(B)- and N; B is H or B forms a bond with either R5 or R7; R1 = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8-cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C3-C8-cycloalkyl C1-C6 alkyl, heterocycloalkyl C1-C6 alkyl, heteroaryl C1-C6 alkyl, amino and alkoxy; R2 = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8-cycloalkyl, heterocycloalkyl, alkoxy, aryl and heteroaryl; R3 = H, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl; R4, R5, R6 and R7 = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl; or R4 and R7 form together a -CH2- linkage; n is an integer = 1, 2, 3, 4, 5 and 6; Carbons (2) and (3) are two chiral centers, wherein chiral center (2) has a configuration = S and R and wherein chiral center (3) has a S configuration as well as pharmaceutically acceptable salts thereof. Methods of preparation are claimed and prepns. and/or characterization data for .apprx.90 examples of I are included. For example, II was prepared from a 55/45 mixture of (2S)- and (2R)-pentafluorophenyl 2-((4S)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)-4-methylpentanoate (preparation by partial diastereoisomerization of latter isomer) by 1st creating an amide linkage using 1-(2-pyridyl)piperazine (40 %) and then a 2nd amide linkage using hydroxylamine (31 %). IC50 values for inhibition of MMP-1, MMP-2, MMP-9 and MMP-12 by 16 examples of I are tabulated. Also, percentage of inhibition of IL-2-induced peritoneal recruitment of lymphocytes (model for cellular migration that occurs during inflammation) by 8 examples of I are tabulated.

IT 874646-52-3P, (2S,3S)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[(2R)-2-methyl-4-(pyridin-2-yl)piperazin-1-yl]carbonyl]hexanamide 874646-54-5P, (2S,3S)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[(2S)-2-methyl-4-(2-pyridinyl)piperazin-1-yl]carbonyl]hexanamide 874646-56-7P, (2S,3S)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[(2R)-2-methyl-4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl]hexanamide 874646-58-9P, (2S,3S)-6-(4-Ethoxyphenyl)-3-[[(2R)-4-(2-fluorophenyl)-2-methylpiperazin-1-yl]carbonyl]-N-hydroxy-2-hydroxyhexanamide 874646-79-4P, (2S,3R)-6-(4-Ethoxyphenyl)-3-[[4-(4-fluorophenyl)piperazin-1-yl]carbonyl]-N-hydroxy-2-hydroxyhexanamide 874646-82-9P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]carbonyl]hexanamide 874646-85-2P, (2S,3R)-3-[[4-(5-Cyanopyridin-2-yl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl]-N-hydroxy-2-hydroxyhexanamide 874646-86-3P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-(6-methylpyridin-2-yl)piperazin-1-yl]carbonyl]hexanamide 874646-87-4P, (2S,3R)-3-[[4-(6-Chloropyridin-2-yl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl]-N-hydroxy-2-hydroxyhexanamide 874646-88-5P, (2S,3R)-3-[[4-(5-Chloropyridin-2-yl)piperazin-1-yl]carbonyl)-6-(4-ethoxyphenyl]-N-hydroxy-2-hydroxyhexanamide 874646-89-6P, (2S,3R)-3-[[4-(4-Chloro-2-fluorophenyl)piperazin-1-yl]carbonyl)-6-(4-ethoxyphenyl]-N-hydroxy-2-hydroxyhexanamide 874646-92-1P, (2S,3R)-3-[[4-(2-Chlorophenyl)piperazin-1-yl]carbonyl)-6-(4-ethoxyphenyl]-N-hydroxy-2-hydroxyhexanamide 874646-93-2P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-(6-methyl-2-(trifluoromethyl)quinolin-4-yl]piperazin-1-yl]carbonyl]hexanamide 874646-94-3P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]carbonyl]hexanamide 874646-95-4P, (2S,3R)-3-[[4-(3,5-Dichloropyridin-4-yl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874646-96-5P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-(2-methoxyphenyl)piperazin-1-yl]carbonyl]hexanamide 874646-97-6P, (2S,3R)-3-[[4-(4-Chlorophenyl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874646-98-7P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl]hexanamide 874646-99-8P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-(2-(morpholin-4-yl)ethyl]piperazin-1-yl]carbonyl]hexanamide 874647-00-4P, (2S,3R)-3-[[4-(2-Cyanophenyl)piperazin-1-

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

yl]carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874647-01-5P, (2S,3R)-3-[[4-(2-Fluorophenyl)piperazin-1-yl]carbonyl]-N-hydroxy-2-hydroxy-6-[4-(trifluoromethoxy)phenyl]hexanamide 874647-02-6P, (2S,3R)-3-[[4-(6-Chloropyridin-2-yl)piperazin-1-yl]carbonyl]-N-hydroxy-2-hydroxy-6-[4-(trifluoromethoxy)phenyl]hexanamide 874647-04-8P, (2S,3R)-N-Hydroxy-2-hydroxy-3-[[4-(pyridin-2-yl)piperazin-1-yl]carbonyl)-6-[4-(trifluoromethoxy)phenyl]hexanamide 874647-15-1P, (2S,3R)-6-(4-Ethoxyphenyl)-3-[[(1S,4S)-5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]carbonyl]-N-hydroxy-2-hydroxyhexanamide 874647-38-8P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-[2-(2-thienyl)ethyl]piperazin-1-yl]carbonyl]hexanamide 874647-40-2P, (2S,3R)-3-[(4-Cyclohexylpiperazin-1-yl)carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874647-54-8P, (2R,3S)-3-Benzyl-N-hydroxy-2-hydroxy-4-oxo-4-[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]butanamide 874647-55-9P, (2S,3S)-3-Benzyl-N-hydroxy-2-hydroxy-4-[(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]-4-oxobutanamide 874647-73-1P, (2S,3S)-3-(Cyclopentylmethyl)-N-hydroxy-2-hydroxy-4-[(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]-4-oxobutanamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of piperazine and related N-hydroxy succinic acid diamide derivs. as metalloproteinase inhibitors with therapeutic uses)

RN 874646-52-3 HCAPLUS

CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-2-methyl-γ-oxo-4-(2-pyridinyl)-, (αS,βS,2R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 874646-54-5 HCAPLUS

CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-2-methyl-γ-oxo-4-(2-pyridinyl)-, (αS,βS,2S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 874646-56-7 HCAPLUS

CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-2-methyl-γ-oxo-4-(2-pyrimidinyl)-, (αS,βS,2R)-(CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 874646-58-9 HCAPLUS

CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-4-(2-fluorophenyl)-N,α-dihydroxy-2-methyl-γ-oxo-, (αS,βS,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-79-4 HCAPLUS

CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-4-(4-fluorophenyl)-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-82-9 HCAPLUS

CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-4-[5-(trifluoromethyl)-2-pyridinyl]-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-85-2 HCAPLUS

CN 1-Piperazinebutanamide, 4-(5-cyano-2-pyridinyl)-β-[3-(4-

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 874646-86-3 HCAPLUS
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-4-(6-methyl-2-pyridinyl)-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-87-4 HCAPLUS
CN 1-Piperazinebutanamide, 4-(6-chloro-2-pyridinyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 874646-88-5 HCAPLUS
CN 1-Piperazinebutanamide, 4-(5-chloro-2-pyridinyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)-
(CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 874646-94-3 HCAPLUS
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-4-[3-(trifluoromethyl)-2-pyridinyl]-,
(αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-95-4 HCAPLUS
CN 1-Piperazinebutanamide, 4-(3,5-dichloro-4-pyridinyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 874646-96-5 HCAPLUS
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-4-(2-methoxyphenyl)-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 874646-89-6 HCAPLUS
CN 1-Piperazinebutanamide, 4-(4-chloro-2-fluorophenyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 874646-92-1 HCAPLUS
CN 1-Piperazinebutanamide, 4-(2-chlorophenyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 874646-93-2 HCAPLUS
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-4-[6-methyl-2-(trifluoromethyl)-4-quinolinyl]-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 874646-97-6 HCAPLUS
CN 1-Piperazinebutanamide, 4-(4-chlorophenyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 874646-98-7 HCAPLUS
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-4-(2-pyrazinyl)-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-99-8 HCAPLUS
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-4-[2-(4-morpholinyl)ethyl]-γ-oxo-, (αS,βR)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 874647-00-4 HCAPLUS
CN 1-Piperazinebutanamide, 4-(2-cyanophenyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)-
(CA INDEX NAME)

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Absolute stereochemistry.



RN 874647-01-5 HCAPLUS
CN 1-Piperazinebutanamide, 4-(2-fluorophenyl)-N,α-dihydroxy-γ-oxo-β-[3-[4-(trifluoromethoxy)phenyl]propyl]-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-02-6 HCAPLUS
CN 1-Piperazinebutanamide, 4-(6-chloro-2-pyridinyl)-N,α-dihydroxy-γ-oxo-β-[3-[4-(trifluoromethoxy)phenyl]propyl]-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-04-8 HCAPLUS
CN 1-Piperazinebutanamide, N,α-dihydroxy-γ-oxo-4-(2-pyridinyl)-β-[3-[4-(trifluoromethoxy)phenyl]propyl]-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 1-Piperazinebutanamide, N,α-dihydroxy-γ-oxo-β-(phenylmethyl)-4-[4-(trifluoromethoxy)phenyl]-, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-55-9 HCAPLUS
CN 1-Piperazinebutanamide, N,α-dihydroxy-2-methyl-γ-oxo-β-(phenylmethyl)-4-[4-(trifluoromethoxy)phenyl]-, (αS,βS,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-73-1 HCAPLUS
CN 1-Piperazinebutanamide, β-(cyclopentylmethyl)-N,α-dihydroxy-2-methyl-γ-oxo-4-[4-(trifluoromethoxy)phenyl]-, (αS,βS,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 874647-15-1 HCAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane-2-butanamide, β-[3-(4-ethoxyphenyl)propyl]-5-(4-fluorophenyl)-N,α-dihydroxy-γ-oxo-, (αS,βR,1S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-38-8 HCAPLUS
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-4-[2-(2-thienyl)ethyl]-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-40-2 HCAPLUS
CN 1-Piperazinebutanamide, 4-cyclohexyl-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-54-8 HCAPLUS

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 13:21:22 ON 02 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 13:21:22 ON 02 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:21:22 ON 02 MAY 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l13 tot
```

L13 ANSWER 1 OF 1 USPATFULL on STN

AN 2006:328715 USPATFULL

TI Derivatives of hydroxamic acid as metalloproteinase inhibitors

IN Pain, Gilles, Bresso, ITALY
Davies, Stephen John, Oxfordshire, UNITED KINGDOM
Bombrun, Agnes, Monnetier-Mornex, FRANCE

PA Vernalis (Oxford) Limited, Abington, UNITED KINGDOM, CB1 6GB (non-U.S. corporation)
Laboratoires Serono S.A., Aubonne, SWITZERLAND, CH-1170 (non-U.S. corporation)

PI US-20060281920 A1 20061214
AI 2004US-000568433 A1 20040818 (10)
2004WO-GB0003558 20040818
20060808 PCT 371 date
PRAI 2003GB-000019917 20030823
2003GB-000028632 20031210
DT Utility
FS APPLICATION
LREP BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2027

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula (I) are inhibitors of matrix metalloproteinases, and are of use in the treatment of, for example fibrotic disease, multiple sclerosis, emphysemia, bronchitis and asthma; formula (I) whereIn Ar represents an optionally substituted aryl, heteroaryl, C.sub.3-C.sub.8 cycloalkyl or heterocycloakyl group; R represents hydrogen or C.sub.1-C.sub.6 alkyl, or C.sub.3-C.sub.6 cycloalkyl; Alk represents a divalent C.sub.1-C.sub.5 alkylene or C.sub.2-C.sub.5 alkenylene radical; and R.sub.1 and R.sub.2 taken together with the nitrogen atom to which they are attached form a first heterocycloalkyl ring which is optionally fused to a second C.sub.3-C.sub.8 cycloalkyl or heterocycloalkyl ring, the said first and second rings being optionally substituted by at least one group of formula (II): formula (II) wherein m, p and n are independently 0 or 1; Z represents, hydrogen, or an optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms which is optionally fused to another optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms; Alk.sup.1 and Alk.sup.2 independently represent optionally substituted divalent C.sub.1-C.sub.3 alkylene radicals; X represents --O--, --S--, --S(O)--, --S(O.sub.2)--, --C(.dbd.O)--, --NH--, --NR.sub.3--, --S(O.sub.2)NH--, --S(O.sub.2)NR.sub.3--, --NHS(O.sub.2)--, or --NR.sub.3S(O.sub.2)--, where R.sub.3 is C.sub.1-C.sub.3 alkyl. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 847037-74-5P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(3-methoxyphenyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847037-76-7P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(4-methoxyphenyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847037-78-9P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(pyridin-2-yl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847037-80-3P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(pyridin-4-yl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847037-92-7P, (3R)-[[4-[(Benzodioxol-5-yl)methyl]piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847037-94-9P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(pyridin-4-yl)methyl]piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847037-96-1P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-benzylpiperazin-1-yl)carbonyl]hexanoic acid hydroxyamide 847037-98-3P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-00-0P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(4-trifluoromethylpyrimidin-2-yl]piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-02-2P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(4-chloropyrimidin-2-yl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-04-4P, (3R)-[[4-(4,6-Dimethoxy-[1,3,5]triazin-2-yl]piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-06-6P,

L13 ANSWER 1 OF 1 USPATFULL on STN (Continued)

6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(3-trifluoromethylphenyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-08-8P 847038-19-1P 847038-21-5P, (3R)-[((3S)-Benzyl-4-benzylpiperazin-1-yl)carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-23-7P 847038-26-0P, 4-[4-[(Benzodioxol-5-yl)methyl]piperazin-1-yl]-(2S)-hydroxy-N-hydroxy-4-oxo-(3R)-(4-trifluoromethoxybenzyl]butyramide 847038-34-0P, 4-[4-[(Benzodioxol-5-yl)methyl]piperazin-1-yl]-(3R)-(4-benzyloxybenzyl)-(2S)-hydroxy-N-hydroxy-4-oxobutyramide 847038-40-8P, 6-[3,5-Bis(trifluoromethyl)phenyl]-(2S)-hydroxy-(3R)-[[4-(pyridin-2-yl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-46-4P, (3R)-[((2S)-Benzyl-4-methylpiperazin-1-yl)carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-48-6P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-[(4-trifluoromethoxyphenyl)sulfonyl]piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-50-0P, 6-[4-Ethoxyphenyl]-(2S)-hydroxy-(3R)-[[4-(4-tolylsulfonyl)piperazin-1-yl]carbonyl]hexanolc acid hydroxyamide 847038-52-2P, (3R)-[[4-[(5-Bromothien-2-yl)sulfonyl]piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-54-4P, (3R)-[[4-[(5-Phenylsulfonylthien-2-yl)sulfonyl]piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-56-6P, (3R)-[[4-(4-Butoxyphenylsulfonyl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-58-8P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(4-methoxy-2,3,6-trimethylphenylsulfonyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-60-2P, (3R)-[[4-[(3,4-Dimethoxyphenyl)sulfonyl]piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-62-4P, 6-(4-Methoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(2-fluorophenyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-64-6P, 6-(4-Methoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(pyridin-2-yl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-66-8P, 6-(4-Fluorophenyl)-(3R)-[[4-(2-fluorophenyl)piperazin-1-yl]carbonyl]-(2S)-hydroxyhexanoic acid hydroxyamide 847038-68-0P, 6-(4-Fluorophenyl)-(2S)-hydroxy-(3R)-[[4-(pyridin-2-yl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide 847038-70-4P, (3R)-[[4-Benzyl-(2S)-methylpiperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-72-6P, (3R)-[(4-Benzyl-(2S)-methylpiperazin-1-yl)carbonyl]-6-(4-methoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-74-8P, (3R)-[(4-Benzyl-(2S)-isobutylpiperazin-1-yl)carbonyl]-6-(4-methoxyphenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-76-0P, (3R)-[(4-Benzyl-(2S)-methylpiperazin-1-yl)carbonyl]-6-(4-fluorophenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-78-2P, (3R)-[(4-Benzyl-(2S)-isobutylpiperazin-1-yl)carbonyl]-6-(4-fluorophenyl)-(2S)-hydroxyhexanoic acid hydroxyamide 847038-80-6P, 4-[5-(4-Ethoxyphenyl)-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-methylpiperazine-1-carboxylic acid tert-butyl ester 847038-82-8P, 4-[5-(4-Ethoxyphenyl)-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-isobutylpiperazine-1-carboxylic acid tert-butyl ester 847038-84-0P, 4-[5-(4-Methoxyphenyl)-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-methylpiperazine-1-carboxylic acid tert-butyl ester 847038-86-2P, 4-[5-(4-Methoxyphenyl)-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-isobutylpiperazine-1-carboxylic acid tert-butyl ester 847038-88-4P, 4-[5-(4-Fluorophenyl)-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-methylpiperazine-1-carboxylic acid tert-butyl ester 847038-90-8P, 4-[5-(4-Fluorophenyl)-(2R)-[(1S)-(hydroxy)(N-hydroxycarbamoyl)methyl]pentanoyl]-(2S)-isobutylpiperazine-1-carboxylic acid tert-butyl ester 847038-92-0P, 6-(4-Ethoxyphenyl)-(2S)-methoxy-(3R)-[[4-(2-fluorophenyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide
(inhibitor; prepn. of hydroxamates as MMP inhibitors)

IT 847039-40-1P
(preparation of hydroxamates as MMP inhibitors)

IT 847037-74-5P, 6-(4-Ethoxyphenyl)-(2S)-hydroxy-(3R)-[[4-(3-methoxyphenyl)piperazin-1-yl]carbonyl]hexanoic acid hydroxyamide
(inhibitor; preparation of hydroxamates as MMP inhibitors)

L13 ANSWER 1 OF 1 USPATFULL on STN (Continued)

RN 847037-74-5 USPATFULL

CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-4-(3-methoxyphenyl)-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



=> d bib abs hitstr l14 tot

L14 ANSWER 1 OF 1 USPATFULL on STN
AN 2008:23847 USPATFULL
TI N-Hydroxyamide Derivatives and Use Thereof
IN Swinnen, Dominique, Beaumont, FRANCE
Bombrun, Agnes, Chambesy, SWITZERLAND
Gonzalez, Jerome, Annemasse, FRANCE
Crosignani, Stefano, St. Genis-Pouilly, FRANCE
Gerber, Patrick, Etoy, SWITZERLAND
Jorand-Lebrun, Catherine, Contamine-Sarzin, FRANCE
PA Applied Research Systems ARS Holding N.V., Curacao, NETHERLANDS (non-U.S. corporation)
PI US-2008021028 A1 20080124
AI 2005US-000572761 A1 20050725 (11)
2005WO-EP0053616 20050725
20070126 PCT 371 date
PRAI 2004EP-000103574 20040726
2005EP-000100641 20050131
2004US-000591111P 20040726 (60)
2005US-000648924P 20050201 (60)
DT Utility
FS APPLICATION
LREP OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 874646-52-3P, (2S,3S)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[(2R)-2-methyl-4-(pyridin-2-yl)piperazin-1-yl]carbonyl]hexanamide 874646-54-5P, (2S,3S)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[(2S)-2-methyl-4-(2-pyridinyl)piperazin-1-yl]carbonyl]hexanamide 874646-56-7P, (2S,3S)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[(2R)-2-methyl-4-(pyrimidin-2-yl)piperazin-1-yl]carbonyl]hexanamide 874646-58-9P, (2S,3S)-6-(4-Ethoxyphenyl)-3-[[(2R)-4-(2-fluorophenyl)-2-methylpiperazin-1-yl]carbonyl]-N-hydroxy-2-hydroxyhexanamide 874646-79-4P, (2S,3R)-6-(4-Ethoxyphenyl)-3-[[4-(4-fluorophenyl]piperazin-1-yl]carbonyl]-N-hydroxy-2-hydroxyhexanamide 874646-82-9P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]carbonyl]hexanamide 874646-85-2P, (2S,3R)-3-[[4-(5-Cyanopyridin-2-yl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874646-86-3P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-(6-methylpyridin-2-yl)piperazin-1-yl]carbonyl]hexanamide 874646-87-4P, (2S,3R)-3-[[4-(6-Chloropyridin-2-yl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874646-88-5P, (2S,3R)-3-[[4-(5-Chloropyridin-2-yl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874646-89-6P, (2S,3R)-3-[[4-(4-Chloro-2-fluorophenyl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874646-92-1P, (2S,3R)-3-[[4-(2-Chlorophenyl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874646-93-2P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-[6-methyl-2-(trifluoromethyl]quinolin-4-yl]piperazin-1-yl]carbonyl]hexanamide 874646-94-3P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-[3-(trifluoromethyl]pyridin-2-yl]piperazin-1-yl]carbonyl]hexanamide 874646-95-4P, (2S,3R)-3-[[4-(3,5-Dichloropyridin-4-yl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874646-96-5P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-(2-methoxyphenyl)piperazin-1-yl]carbonyl]hexanamide 874646-97-6P, (2S,3R)-3-[[4-(4-Chlorophenyl)piperazin-1-

L14 ANSWER 1 OF 1 USPATFULL on STN (Continued)
yl]carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874646-98-7P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-(pyrazin-2-yl)piperazin-1-yl]carbonyl]hexanamide 874646-99-8P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-[2-(morpholin-4-yl)ethyl]piperazin-1-yl]carbonyl]hexanamide 874647-00-4P, (2S,3R)-3-[[4-(2-Cyanophenyl)piperazin-1-yl]carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874647-01-5P, (2S,3R)-3-[[4-(2-Fluorophenyl]piperazin-1-yl]carbonyl]-N-hydroxy-2-hydroxy-6-[4-(trifluoromethoxy)phenyl]hexanamide 874647-02-6P, (2S,3R)-3-[[4-(6-Chloropyridin-2-yl)piperazin-1-yl]carbonyl]-N-hydroxy-2-hydroxy-6-[4-(trifluoromethoxy)phenyl]hexanamide 874647-04-8P, (2S,3R)-N-Hydroxy-2-hydroxy-3-[[4-(pyridin-2-yl)piperazin-1-yl]carbonyl]-6-[4-(trifluoromethoxy)phenyl]hexanamide 874647-15-1P, (2S,3R)-6-(4-Ethoxyphenyl)-3-[[(1S,4S)-5-(4-fluorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]carbonyl]-N-hydroxy-2-hydroxyhexanamide 874647-38-8P, (2S,3R)-6-(4-Ethoxyphenyl)-N-hydroxy-2-hydroxy-3-[[4-[2-(2-thienyl)ethyl]piperazin-1-yl]carbonyl]hexanamide 874647-40-2P, (2S,3R)-3-[(4-Cyclohexylpiperazin-1-yl)carbonyl]-6-(4-ethoxyphenyl)-N-hydroxy-2-hydroxyhexanamide 874647-54-8P, (2R,3S)-3-Benzyl-N-hydroxy-2-hydroxy-4-oxo-4-[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]butanamide 874647-55-9P, (2S,3S)-3-Benzyl-N-hydroxy-2-hydroxy-4-[(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]-4-oxobutanamide 874647-73-1P, (2S,3S)-3-(Cyclopentylmethyl)-N-hydroxy-2-hydroxy-4-[(2R)-2-methyl-4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]-4-oxobutanamide
(drug candidate; prepn. of piperazine and related N-hydroxy succinic acid diamide derivs. as metalloproteinase inhibitors with therapeutic uses)
RN 874646-52-3 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-2-methyl-γ-oxo-4-(2-pyridinyl)-, (αS,βS,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-54-5 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-2-methyl-γ-oxo-4-(2-pyridinyl)-, (αS,βS,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-56-7 USPATFULL

L14 ANSWER 1 OF 1 USPATFULL on STN (Continued)
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-2-methyl-γ-oxo-4-(2-pyrimidinyl)-, (αS,βS,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-58-9 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-4-(2-fluorophenyl)-N,α-dihydroxy-2-methyl-γ-oxo-, (αS,βS,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-79-4 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-4-(4-fluorophenyl)-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-82-9 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-4-[5-(trifluoromethyl)-2-pyridinyl]-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 1 OF 1 USPATFULL on STN (Continued)



RN 874646-85-2 USPATFULL
CN 1-Piperazinebutanamide, 4-(5-cyano-2-pyridinyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-86-3 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-4-(6-methyl-2-pyridinyl)-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-87-4 USPATFULL
CN 1-Piperazinebutanamide, 4-(6-chloro-2-pyridinyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 1 OF 1 USPATFULL on STN (Continued)

RN 874646-88-5 USPATFULL
CN 1-Piperazinebutanamide, 4-(5-chloro-2-pyridinyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-89-6 USPATFULL
CN 1-Piperazinebutanamide, 4-(4-chloro-2-fluorophenyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-92-1 USPATFULL
CN 1-Piperazinebutanamide, 4-(2-chlorophenyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-93-2 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-4-[6-methyl-2-(trifluoromethyl)-4-quinolinyl]-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-97-6 USPATFULL
CN 1-Piperazinebutanamide, 4-(4-chlorophenyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-98-7 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-4-(2-pyrazinyl)-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-99-8 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-4-[2-(4-morpholinyl)ethyl]-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-00-4 USPATFULL
CN 1-Piperazinebutanamide, 4-(2-cyanophenyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

L14 ANSWER 1 OF 1 USPATFULL on STN (Continued)



RN 874646-94-3 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-4-[3-(trifluoromethyl)-2-pyridinyl]-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-95-4 USPATFULL
CN 1-Piperazinebutanamide, 4-(3,5-dichloro-4-pyridinyl)-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874646-96-5 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-4-(2-methoxyphenyl)-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 1 OF 1 USPATFULL on STN (Continued)

Absolute stereochemistry.



RN 874647-01-5 USPATFULL
CN 1-Piperazinebutanamide, 4-(2-fluorophenyl)-N,α-dihydroxy-γ-oxo-β-[3-[4-(trifluoromethoxy)phenyl]propyl]-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-02-6 USPATFULL
CN 1-Piperazinebutanamide, 4-(6-chloro-2-pyridinyl)-N,α-dihydroxy-γ-oxo-β-[3-[4-(trifluoromethoxy)phenyl]propyl]-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-04-8 USPATFULL
CN 1-Piperazinebutanamide, N,α-dihydroxy-γ-oxo-4-(2-pyridinyl)-β-[3-[4-(trifluoromethoxy)phenyl]propyl]-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 1 OF 1 USPATFULL on STN (Continued)
RN 874647-15-1 USPATFULL
CN 2,5-Diazabicyclo[2.2.1]heptane-2-butanamide, β-[3-(4-ethoxyphenyl)propyl]-5-(4-fluorophenyl)-N,α-dihydroxy-γ-oxo-, (αS,βR,1S,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-38-8 USPATFULL
CN 1-Piperazinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-4-[2-(2-thienyl)ethyl]-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-40-2 USPATFULL
CN 1-Piperazinebutanamide, 4-cyclohexyl-β-[3-(4-ethoxyphenyl)propyl]-N,α-dihydroxy-γ-oxo-, (αS,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-54-8 USPATFULL
CN 1-Piperazinebutanamide, N,α-dihydroxy-γ-oxo-β-(phenylmethyl)-4-[4-(trifluoromethoxy)phenyl]-, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 1 OF 1 USPATFULL on STN (Continued)



RN 874647-55-9 USPATFULL
CN 1-Piperazinebutanamide, N,α-dihydroxy-2-methyl-γ-oxo-β-(phenylmethyl)-4-[4-(trifluoromethoxy)phenyl]-, (αS,βS,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 874647-73-1 USPATFULL
CN 1-Piperazinebutanamide, β-(cyclopentylmethyl)-N,α-dihydroxy-2-methyl-γ-oxo-4-[4-(trifluoromethoxy)phenyl]-, (αS,βS,2R)- (CA INDEX NAME)

Absolute stereochemistry.



```
=> d his

     (FILE 'HOME' ENTERED AT 13:11:49 ON 02 MAY 2008)

     FILE 'HCAPLUS' ENTERED AT 13:12:14 ON 02 MAY 2008
L1            1 US20060281920 /PN

     FILE 'REGISTRY' ENTERED AT 13:12:33 ON 02 MAY 2008

     FILE 'HCAPLUS' ENTERED AT 13:12:33 ON 02 MAY 2008
L2              TRA L1 1- RN :      117 TERMS

     FILE 'REGISTRY' ENTERED AT 13:12:33 ON 02 MAY 2008
L3          117 SEA L2
L4           56 L3 AND NC2NC2/ES
L5              STR
L6            4 L5
L7           73 L5 FULL
                SAV TEM L7 J433C1GIII/A
L8           44 L7 AND L3
L9           29 L7 NOT L8

     FILE 'HCAPLUS' ENTERED AT 13:18:45 ON 02 MAY 2008
L10           1 L8
L11           1 L9

     FILE 'HCAOLD' ENTERED AT 13:19:27 ON 02 MAY 2008
L12           0 L7

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 13:19:36 ON 02 MAY 2008
L13           1 L8
L14           1 L9

=>
```